Insilico Medicine

Insilico Medicine, a Hong Kong-based clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced Wednesday that it has completed a second closing of its Series D round, led by Prosperity7 Ventures, the diversified growth fund of Aramco Ventures, bringing the total Series D financing to $95 million.

Proceeds from the funding will be used to progress Insilico Medicine's current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities, the company added.